Editas Medicine Inc (NASDAQ: EDIT) is -65.15% lower on its value in year-to-date trading and has touched a low of $3.40 and a high of $11.69 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EDIT stock was last observed hovering at around $3.66 in the last trading session, with the day’s loss setting it -0.13%.
Currently trading at $3.53, the stock is -5.37% and -18.70% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.24 million and changing -3.55% at the moment leaves the stock -45.79% off its SMA200. EDIT registered -55.03% loss for a year compared to 6-month loss of -52.04%. The firm has a 50-day simple moving average (SMA 50) of $4.3003 and a 200-day simple moving average (SMA200) of $6.474.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -8.79% gain in the last 1 month and extending the period to 3 months gives it a -28.97%, and is -8.55% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.63% over the week and 5.39% over the month.
Editas Medicine Inc (EDIT) has around 265 employees, a market worth around $291.15M and $67.03M in sales. Profit margin for the company is -288.59%. Distance from 52-week low is 3.82% and -69.80% from its 52-week high. The company has generated returns on investments over the last 12 months (-76.61%).
with sales reaching $2.69M over the same period.The EPS is expected to shrink by -44.10% this year, but quarterly earnings will post -61.40% year-over-year. Quarterly sales are estimated to shrink -49.60% in year-over-year returns.
Editas Medicine Inc (EDIT) Top Institutional Holders
315.0 institutions hold shares in Editas Medicine Inc (EDIT), with institutional investors hold 71.77% of the company’s shares. The shares outstanding are 81.77M, and float is at 81.70M with Short Float at 22.04%. Institutions hold 71.54% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 8.03 million shares valued at $37.51 million. The investor’s holdings represent 9.8032% of the EDIT Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 7.78 million shares valued at $36.34 million to account for 9.498 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 6.0 million shares representing 7.3225% and valued at over $28.02 million, while STATE STREET CORP holds 5.6029 of the shares totaling 4.59 million with a market value of $21.44 million.
Editas Medicine Inc (EDIT) Insider Activity
The most recent transaction is an insider sale by Mei Baisong, the company’s EVP, CHIEF MEDICAL OFFICER. SEC filings show that Mei Baisong sold 518 shares of the company’s common stock on Sep 04 ’24 at a price of $3.42 per share for a total of $1774.0. Following the sale, the insider now owns 0.13 million shares.
Editas Medicine Inc disclosed in a document filed with the SEC on Sep 04 ’24 that O’Neill Gilmore Neil (CEO) sold a total of 1,555 shares of the company’s common stock. The trade occurred on Sep 04 ’24 and was made at $3.42 per share for $5325.0. Following the transaction, the insider now directly holds 0.31 million shares of the EDIT stock.
Still, SEC filings show that on Sep 03 ’24, O’Neill Gilmore Neil (Officer) Proposed Sale 3,000 shares at an average price of $3.92 for $11760.0. The insider now directly holds shares of Editas Medicine Inc (EDIT).
